

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

Karl Bodin^{1*}, Stephan Ellmerich^{1*}, Melvyn C. Kahan¹, Glenys A. Tennent¹, Andrzej Loesch¹, Janet A. Gilbertson¹, Winston L. Hutchinson¹, Palma P. Mangione^{1,2}, J. Ruth Gallimore¹, David J. Millar¹, Shane Minogue³, Amar P. Dhillon⁴, Graham W. Taylor¹, Arthur R. Bradwell^{5,6}, Aviva Petrie⁷, Julian D. Gillmore¹, Vittorio Bellotti^{1,2}, Marina Botto⁸, Philip N. Hawkins¹ & Mark B. Pepys¹

Accumulation of amyloid fibrils in the viscera and connective tissues causes systemic amyloidosis, which is responsible for about one in a thousand deaths in developed countries¹. Localized amyloid can also have serious consequences; for example, cerebral amyloid angiopathy is an important cause of haemorrhagic stroke. The clinical presentations of amyloidosis are extremely diverse and the diagnosis is rarely made before significant organ damage is present¹. There is therefore a major unmet need for therapy that safely promotes the clearance of established amyloid deposits. Over 20 different amyloid fibril proteins are responsible for different forms of clinically significant amyloidosis and treatments that substantially reduce the abundance of the respective amyloid fibril precursor proteins can arrest amyloid accumulation¹. Unfortunately, control of fibril-protein production is not possible in some forms of amyloidosis and in others it is often slow and hazardous¹. There is no therapy that directly targets amyloid deposits for enhanced clearance. However, all amyloid deposits contain the normal, non-fibrillar plasma glycoprotein, serum amyloid P component (SAP)^{2,3}. Here we show that administration of anti-human-SAP antibodies to mice with amyloid deposits containing human SAP triggers a potent, complement-dependent, macrophage-derived giant cell reaction that swiftly removes massive visceral amyloid deposits without adverse effects. Anti-SAP-antibody treatment is clinically feasible because circulating human SAP can be depleted in patients by the bis-D-proline compound CPHPC⁴, thereby enabling injected anti-SAP antibodies to reach residual SAP in the amyloid deposits. The unprecedented capacity of this novel combined therapy to eliminate amyloid deposits should be applicable to all forms of systemic and local amyloidosis.

SAP is selectively concentrated in amyloid deposits by its avid binding to all amyloid fibril types^{2,3}. SAP binding stabilizes amyloid fibrils, protects them from proteolysis *in vitro*⁵ and contributes to the pathogenesis of systemic amyloidosis *in vivo*⁶. Therefore, we developed a new bis-D-proline compound, (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC), which is bound with high affinity by human SAP and triggers its rapid clearance by the liver, thereby depleting circulating SAP by more than 90% for as long as the drug is administered^{4,7}. However, some SAP remains bound to amyloid even after months of CPHPC treatment⁷. Here we show that targeting this residual SAP with immunoglobulin-G (IgG) antibodies triggers the body's potent phagocytic clearance mechanisms (Supplementary Information, section 1).

Splenic and hepatic amyloid A protein (AA) amyloid deposition, closely resembling human systemic AA amyloidosis, was induced by chronic inflammation in C57BL/6 mice deficient in mouse SAP but transgenic for human SAP⁴. Human SAP is present in their circulation,

in normal extracellular matrix^{8,9} (Supplementary Information, section 2) and in the amyloid deposits (Supplementary Information, section 3), just as in humans. Amyloid was quantified in each mouse by whole-body retention of ¹²⁵I-SAP (ref. 10) and the mice were allocated to three groups closely matched for age, sex and amyloid load. The model closely reflects clinical amyloidosis because human SAP binds much more avidly to amyloid than does mouse SAP¹⁰, and CPHPC depletes circulating human but not mouse SAP *in vivo*⁴. Two groups of mice then received CPHPC at 1 mg ml⁻¹ in their drinking water for the rest of the experiment. Circulating human SAP was depleted but, as in humans treated with CPHPC, significant amounts of SAP remained in the amyloid deposits (Supplementary Information, section 4). Five days after starting on CPHPC, one group received a single intraperitoneal injection of 50 mg of the IgG fraction of monospecific polyclonal sheep anti-human-SAP antiserum, containing 7 mg of anti-SAP antibody. A control group received 50 mg of unrelated sheep IgG (Supplementary Information, section 4). The third group received no treatment and thus controlled for spontaneous regression of AA amyloid¹¹. Twenty-eight days after the antibody or control IgG injection, the visceral amyloid load was scored histologically and human SAP was quantified in the individual sera and organs (Supplementary Information, section 4).

There was markedly less amyloid after treatment with CPHPC plus anti-SAP antibody than in the other two groups but there was no difference between CPHPC alone and no treatment (Fig. 1 and Supplementary Information, section 4). Apart from the amyloid deposits there were no other significant histological abnormalities in any animal. Anti-SAP antibody thus produced remarkable regression of amyloid with no disruption to the normal parenchymal or connective-tissue structure of the liver, spleen or other organs. Furthermore, there were no clinical or biochemical adverse effects, no mice died during the experiment and body weights remained constant (Supplementary Information, section 5).

Systemic amyloid deposits are characteristically acellular with no surrounding inflammatory reaction (Figs 2l, p, 3a). However, by 24 h after injection of anti-SAP antibody all the deposits were densely infiltrated with mononuclear inflammatory cells and some granulocytes (Fig. 2b, m, q). Most infiltrating cells stained strongly with antibody to F4/80, a global macrophage marker (Fig. 2b). No such staining was present in the amyloid deposits of mice not receiving anti-SAP. On day 2, the macrophages surrounding the amyloid were fusing to form multinucleate giant cells and stained strongly for CD68, a marker of phagocyte endocytotic activity that co-localized with staining for the amyloid fibril AA protein and mouse complement component C3 (Figs 2e-k, 3b, c and Supplementary Information, section 6). By day 4 the deposits were less abundant and were fragmented by numerous multinucleate giant cells surrounding and engulfing islands of amyloid (Fig. 2c-e, n, r). At day 7,

¹Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK. ²Dipartimento di Biochimica, Università di Pavia, Via Taramelli 3b, 27100 Pavia, Italy. ³Centre for Molecular Cell Biology, Division of Medicine, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK. ⁴Department of Histopathology, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK. ⁵Department of Immunity and Infection, The Medical School, University of Birmingham, Birmingham B15 2TT, UK. ⁶The Binding Site Ltd, Birmingham B14 4ZB, UK. ⁷Biostatistics Unit, UCL Eastman Dental Institute, 256 Grays Inn Road, London WC1X 8LD, UK. ⁸Rheumatology Section, Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK.

*These authors contributed equally to this work.




Figure 1 | Elimination of visceral amyloid in AA amyloidotic mice after treatment with anti-SAP antibody. **a–f**, Systemic AA amyloidosis was established in C57BL/6 SAP-deficient mice transgenically expressing human SAP, which were allocated to three groups closely matched for age, sex and whole-body amyloid load, the latter shown as mean (standard deviation) per cent whole-body retention of ^{125}I -human SAP tracer (one-way ANOVA comparing the three group means, $P = 0.054$). The mice were treated with CPHPC and a single dose of sheep anti-human-SAP antibody (group 1, $n = 31$), with CPHPC and the same dose of an irrelevant sheep anti-human antibody (group 2, $n = 30$), or left untreated (group 3, $n = 32$). Amyloid load was determined histologically 28 days later. **a**, Each point is an individual spleen amyloid score. 0, no amyloid detected; 1, one or more trace specks; 2, marginal zone traces; 3, general marginal zone deposits; 4, heavy marginal zone deposits; 5, heavy marginal zone and extensive interfollicular deposits. Kruskal–Wallis

residual amyloid was mostly being degraded within the cytoplasm of decreasing numbers of giant cells. Amyloid clearance was largely complete by about day 16 with remarkable restoration of normal tissue architecture and absence of any residual cellular infiltrate (Fig. 2o, s).

Human SAP binds avidly to mouse AA deposits *in vivo* and persists there with a half-life of 3–4 days, whereas circulating human SAP is cleared in mice with a half-life of 3–4 h and is undetectable in the plasma after 3 days^{4,10}. Amyloid deposits in non-transgenic AA amyloidotic C57BL/6 mice were thus loaded with human SAP by a single intraperitoneal injection of 10 mg of the isolated pure protein and anti-human-SAP antibody was injected 3 days later without the need for CPHPC. The same highly reproducible amyloid elimination occurred

test comparing the 3 groups, $P < 0.0001$. Dunn's multiple comparison test: 1 versus 2, $P < 0.001$; 1 versus 3, $P < 0.001$; 2 versus 3, not significant, $P > 0.05$. **b**, Congo-red-stained spleen section showing the pathognomonic amyloid green dichroism, score = 5. **c**, As in **b** but with amyloid score = 1; single amyloid speck is arrowed. **d**, Individual liver amyloid scores. 0, no amyloid detected; 1, trace specks; 2, traces in/around most portal tracts; 3, significant deposits in/around all portal tracts; 4, extensive portal and parenchymal deposits. Kruskal–Wallis test, $P < 0.0001$. Dunn's multiple comparison test: 1 versus 2, $P < 0.001$; 1 versus 3, $P < 0.001$; 2 versus 3, not significant, $P > 0.05$. There were no significant differences in the average spleen or liver amyloid scores between males and females within any of the groups (not shown). **e**, Congo-red stain of liver amyloid, score = 4. **f**, Liver amyloid score = 1; arrows indicate amyloid specks. All tissue micrographs are at $\times 100$ magnification.

as in the human SAP transgenic mice and this approach facilitated analysis of the mechanisms responsible.

In contrast to the clearance of amyloid deposits in wild-type mice, significantly more amyloid remained after anti-SAP treatment of complement-deficient animals lacking either C1q (ref. 12) or C3 (ref. 13) (Supplementary Information, section 7), demonstrating that the antibody effect is largely complement dependent. IgG antibody alone could potentially engage phagocytic cells via their Fc γ receptors and, although amyloid clearance was much reduced in the absence of complement, the persistent deposits in complement-deficient mice were more fragmented than in untreated controls, indicating some direct antibody effect. There was more complete amyloid elimination




Figure 2 | Cellular infiltration and amyloid destruction after administration of anti-SAP antibody. **a**, Congo-red-stained spleen section one day after anti-SAP-antibody treatment showing typical heavy marginal zone amyloid. **b**, Anti-F4/80-stained adjacent section showing intense infiltration of the amyloid deposits with phagocytic cells. **c**, Haematoxylin-and-eosin-stained spleen section 4 days after anti-SAP-antibody treatment, showing multiple multinucleate giant cells surrounding and engulfing amyloid in the marginal zone. **d**, Congo-red-stained adjacent section showing marked fragmentation and reduction of marginal zone amyloid. **e**, Anti-CD68-stained adjacent section, showing massive infiltration of the marginal zone amyloid by phagocytically active macrophages and giant cells. **f**, Anti-CD68-stained spleen section from a control, untreated amyloidotic mouse, showing no positive cells in the pale amorphous marginal zone amyloid deposits. Scale bars in **a–f** are 100 μm . **g**, Splenic marginal zone amyloid deposit from a mouse 4 days after treatment with anti-SAP antibody, stained with antibodies to mouse AA, the amyloid fibril protein. **h**, Adjacent section stained with anti-mouse complement component C3. **i**, Adjacent section stained with anti-mouse CD68. Scale bars in **g–i** are 20 μm . **j**, Extended focus confocal view (Z projection) of the same spleen immunostained for CD68 (red), human serum

in some C1q-deficient mice than in C3-deficient mice (Supplementary Information, section 7), indicating that complement activation may occur in the absence of C1q but that C3 is critical. Consistent with this observation, F(ab)₂ anti-SAP-antibody treatment reduced amyloid load but was significantly less effective than intact IgG antibody (Supplementary Information, section 8). F(ab)₂ antibodies activate the alternative pathway, independently of C1q, and it is likely that the high dose of F(ab)₂ that was used (Supplementary Information, section 8) triggered some complement activation. Full efficacy of the anti-SAP antibody thus requires the Fc region but cellular recognition by Fc γ receptors is not a major factor as F(ab)₂ was more effective in complement-sufficient mice than IgG antibody was in complement-deficient mice.

When macrophage activity was ablated using liposomal clodronate¹⁴, anti-SAP antibody produced no reduction of amyloid load

amyloid A protein (SAA) (green) and counterstained with Hoechst 33342 (blue), confirming the close co-localization of amyloid and active phagolysosome fusion in macrophages and giant cells as they ingest and destroy the amyloid deposits that have been opsonised by anti-SAP antibody and complement. Scale bar, 5 μm . **k**, Orthogonal views of the same stain as **j**, showing ingested amyloid within a macrophage. **l–o**, Spleen (**l–o**; scale bars, 20 μm) and liver (**p–s**; magnification, $\times 250$), thin sections from mice in this experiment stained with toluidine blue. Control mice, not treated with anti-SAP antibody, show abundant amorphous amyloid deposits, pale blue in spleen (red arrows, **l**) and pink in liver (**p**) with the characteristic absence of any surrounding inflammatory reaction or cellular infiltrate. **m**, **q**, One day after anti-SAP antibody treatment showing intense, predominantly mononuclear cell infiltration (**m**, red arrows) in and around the amyloid. **n**, **r**, Five days after anti-SAP-antibody treatment showing fusion of macrophages to form multinucleate giant cells surrounding and infiltrating the deposits and containing large masses of ingested amyloid undergoing degradation. **o**, **s**, Sixteen days after anti-SAP-antibody administration showing complete elimination of amyloid deposits with no residual cellular infiltrate and restoration of normal tissue architecture.

(Supplementary Information, section 9), demonstrating that macrophages were the essential final effectors of amyloid clearance. Macrophages are largely responsible for the normal, clinically silent resolution of non-infective tissue injury and for remodelling of non-cellular matrix. The failure to spontaneously clear amyloid deposits—which are composed only of autologous constituents—is therefore remarkable, especially as, despite their inherent stability, amyloid fibrils can be digested by proteinases and phagocytic cells *in vitro*⁵, particularly when opsonised by antibody¹⁵. *In vivo* macrophage responses to different types of amyloid have been reported occasionally^{16–19}, and amyloid deposits sometimes regress when fibril-precursor-protein abundance is sufficiently reduced^{20,21}. However, amyloid usually accumulates with little or no local cellular or systemic inflammatory response. The serendipitous effect of CPHPC in depleting circulating SAP but leaving some SAP in amyloid deposits enabled the present use of




Figure 3 | Electron micrographs of amyloid destruction after anti-SAP-antibody treatment. **a**, Spleen and liver from a control AA amyloidotic mouse loaded with human SAP, which did not receive anti-SAP antibody, showing extracellular masses of fibrillar amyloid with the characteristic absence of any inflammatory cells or cellular reaction. Scale bars, 3 μ m. **b**, Liver from an AA amyloidotic mouse loaded with human SAP, examined 5 days after administration of anti-SAP antibody, showing a multinucleate giant cell surrounding, internalizing and digesting large masses of amyloid. Scale bar, 5 μ m. **c**, Anti-CD68 immunostain of spleen removed one day after administration of anti-SAP antibody to an AA amyloidotic mouse loaded with human SAP, showing a macrophage surrounding, infiltrating and ingesting amyloid. The dark peroxidase reaction product (white arrows) identifies phagolysosome fusion around internalized fragments of amyloid. Scale bar, 1 μ m.

produced by the sheep polyclonal anti-human SAP, and which had similar plasma half lives of \sim 4 days in wild-type C57BL/6 mice. IgG2a antibodies were selected because mouse IgG1 activates mouse complement poorly if at all²². SAP-5 and Abp1 recognized different epitopes on human SAP (Supplementary Information, section 10) but were each as potent as the polyclonal sheep anti-SAP in eliminating amyloid *in vivo* (Supplementary Information, sections 11 and 12).

Anti-SAP antibody could potentially elicit tissue-damaging inflammation in amyloidotic tissues. However, the present notable absence of any adverse effects presumably reflects the physiological nature of the macrophage reaction and is encouraging for the clinical use of CPHPC and anti-SAP. Nevertheless, appropriate caution will be essential because systemic amyloidosis patients have widespread amyloid deposits in sensitive tissues, including the heart, blood-vessel walls and nerves, which are not involved in the mouse AA model. Also, the trace amount of human SAP in normal glomerular basement membrane⁸ and elastic fibre microfibrils⁹ is a potential undesirable target for anti-SAP antibodies. It is therefore reassuring that there was no change in plasma biochemistry or any histological abnormality in human SAP transgenic mice treated with CPHPC followed by anti-human SAP antibodies (Supplementary Information, section 13).

Antibodies to amyloid β -protein (A β) are under intense investigation for the treatment of Alzheimer's disease and an *in vivo* imaging study²³ has shown binding to some human systemic immunoglobulin-light-chain amyloid (AL) deposits by a monoclonal anti-light-chain antibody that produces clearance of artefactual local human AL amyloidomas in mice^{24,25}. However, therapeutic anti-fibril antibodies will have to be reactive with each different type of amyloid whereas anti-SAP-antibody treatment is applicable to all forms of amyloid and all human amyloid deposits. Because the SAP that is universal in amyloid is derived from the circulation, anti-SAP antibodies and complement proteins will also be able to reach the deposits, and macrophages are present in, or can access, all tissues. Management of systemic amyloidosis will always require maximum efforts to reduce amyloid-fibril-precursor-protein production, if that is feasible, but the capacity to eliminate existing amyloid deposits would be a major therapeutic advance. We are now working towards clinical evaluation of this approach, and a candidate monoclonal anti-SAP antibody has been fully humanized for the exploration of safety, efficacy and optimal clinical dosing.

METHODS SUMMARY

Induction of murine AA amyloidosis using amyloid enhancing factor and repeated casein injections, estimation of amyloid load *in vivo* and *in vitro*, and quantification of human SAP in serum and tissue extracts, were conducted as previously reported^{4,6,10}. Sheep and mouse anti-human-SAP antibodies were raised by immunization with isolated pure human SAP²⁶ and mouse anti-human-SAP hybridomas were cloned by standard methods; Abp1 was produced by AbPro.

Received 29 June; accepted 13 September 2010.

Published online 20 October 2010.

anti-SAP antibodies to trigger unprecedented, clinically silent elimination of visceral amyloid deposits by macrophages.

The same therapeutic approach should be effective in human amyloidosis, using human or humanized monoclonal antibodies or other antibody constructs. Therefore we investigated two of our mouse monoclonal IgG2a anti-SAP antibodies, designated SAP-5 and Abp1, which bound to human SAP with similar affinities, on rates and off rates (Supplementary Information, section 10), which activated mouse complement *in vitro* producing C3 cleavage comparable to that

1. Pepys, M. B. Amyloidosis. *Annu. Rev. Med.* **57**, 223–241 (2006).
2. Pepys, M. B., Dyck, R. F., de Beer, F. C., Skinner, M. & Cohen, A. S. Binding of serum amyloid P component (SAP) by amyloid fibrils. *Clin. Exp. Immunol.* **38**, 284–293 (1979).
3. Pepys, M. B. *et al.* Amyloid P component. A critical review. *Amyloid* **4**, 274–295 (1997).

4. Pepys, M. B. *et al.* Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. *Nature* **417**, 254–259 (2002).
5. Tennent, G. A., Lovat, L. B. & Pepys, M. B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis. *Proc. Natl Acad. Sci. USA* **92**, 4299–4303 (1995).
6. Botto, M. *et al.* Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. *Nature Med.* **3**, 855–859 (1997).
7. Gillmore, J. D. *et al.* Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. *Br. J. Haematol.* **148**, 760–767 (2010).
8. Dyck, R. F. *et al.* Amyloid P-component is a constituent of normal human glomerular basement membrane. *J. Exp. Med.* **152**, 1162–1174 (1980).
9. Breathnach, S. M. *et al.* Amyloid P component is located on elastic fibre microfibrils of normal human tissues. *Nature* **293**, 652–654 (1981).
10. Hawkins, P. N., Myers, M. J., Epenetos, A. A., Caspi, D. & Pepys, M. B. Specific localization and imaging of amyloid deposits *in vivo* using ¹²⁵I-labeled serum amyloid P component. *J. Exp. Med.* **167**, 903–913 (1988).
11. Hawkins, P. N. & Pepys, M. B. A primed state exists *in vivo* following histological regression of amyloidosis. *Clin. Exp. Immunol.* **81**, 325–328 (1990).
12. Botto, M. *et al.* Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. *Nature Genet.* **19**, 56–59 (1998).
13. Wessels, M. R. *et al.* Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. *Proc. Natl Acad. Sci. USA* **92**, 11490–11494 (1995).
14. Van Rooijen, N. & Hendriks, E. Liposomes for specific depletion of macrophages from organs and tissues. *Methods Molec. Biol.* **605**, 189–203 (2009).
15. Zucker-Franklin, D. Immunophagocytosis of human amyloid fibrils by leukocytes. *J. Ultrastruct. Res.* **32**, 247–257 (1970).
16. Argilés, À., García García, M. & Mourad, G. Phagocytosis of dialysis-related amyloid deposits by macrophages. *Nephrol. Dial. Transplant.* **17**, 1136–1138 (2002).
17. Nakamura, Y. *et al.* A case of hereditary amyloidosis transthyretin variant Met 30 with amyloid cardiomyopathy, less polyneuropathy, and the presence of giant cells. *Pathol. Int.* **49**, 898–902 (1999).
18. Verine, J. *et al.* Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. *Hum. Pathol.* **38**, 1798–1809 (2007).
19. Weiss, S. W. & Page, D. L. Amyloid nephropathy of Ostertag with special reference to renal glomerular giant cells. *Am. J. Pathol.* **72**, 447–455 (1973).
20. Lachmann, H. J. *et al.* Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. *Br. J. Haematol.* **122**, 78–84 (2003).
21. Lachmann, H. J. *et al.* Natural history and outcome in systemic AA amyloidosis. *N. Engl. J. Med.* **356**, 2361–2371 (2007).
22. Klaus, G. G. B., Pepys, M. B., Kitajima, K. & Askonas, B. A. Activation of mouse complement by different classes of mouse antibody. *Immunology* **38**, 687–695 (1979).
23. Wall, J. S. *et al.* Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. *Blood*. doi:10.1182/blood-2010-03-273797 (3 June 2010).
24. Solomon, A., Weiss, D. T. & Wall, J. S. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. *Cancer Biother. Radiopharm.* **18**, 853–860 (2003).
25. Solomon, A., Weiss, D. T. & Wall, J. S. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11–1F4. *Clin. Cancer Res.* **9**, 3831S–3838S (2003).
26. de Beer, F. C. & Pepys, M. B. Isolation of human C-reactive protein and serum amyloid P component. *J. Immunol. Methods* **50**, 17–31 (1982).

Supplementary Information is linked to the online version of the paper at www.nature.com/nature.

Acknowledgements The study was supported by Medical Research Council Programme Grant G97900510 to M.B.P. and P.N.H. and by the University College London Amyloidosis Research Fund. K.B. was supported by the Erik and Edith Fernströms Foundation for Medical Research and a Postdoctoral Fellowship from the Swedish Research Council. K.B. dedicates his work to his late father, Gunnar Bodin. We thank S. Gordon, S. Wood, S. Kolstoe, J. Raynes, P. Simons and R. Al-Shawi for information, advice, reagents and support, and B. Jones for processing the manuscript.

Author Contributions The study was conceived, designed and supervised by M.B.P. K.B., M.C.K. and S.E. performed all the experimental animal work. G.A.T., A.L., J.A.G., S.M. and A.P.D. performed or contributed to the histological studies. Amyloid scoring was performed by K.B., M.C.K., S.E., J.D.G. and M.B.P. W.L.H., P.P.M., J.R.G., D.J.M., G.W.T. and V.B. conducted the immunochemical, radiochemical and immunoassay studies. A.P. undertook the statistical analyses. A.R.B. produced the sheep anti-human SAP and control antisera. M.B. supplied the complement knockout mice. J.D.G. and P.N.H. contributed to experimental design. The paper was written by M.B.P. and reviewed and approved by all co-authors.

Author Information Reprints and permissions information is available at www.nature.com/reprints. The authors declare competing financial interests: details accompany the full-text HTML version of the paper at www.nature.com/nature. Readers are welcome to comment on the online version of this article at www.nature.com/nature. Correspondence and requests for materials should be addressed to M.B.P. (m.pepys@ucl.ac.uk).